iiinova — where your digital self keeps evolving

Devin Effinger, Ph.D

@deffinger.bsky.social

1.5K followers 1K following 31 posts

Neuropharmacology PhD | postdoc researching #psychedelics at CU Anschutz | Lived experience w/ TBI & SUD recovery | Board member, Winter Conference on Brain Research | linktr.ee/Devin_Effinger NIDA IRP > UNC Chapel Hill > CU Anschutz

Posts Replies Media

Devin Effinger, Ph.D @deffinger.bsky.social · 31/07/2025

It’s wild how much change is possible in this life. From relearning to talk post-TBI, to full blown heroin addiction, to a life beyond anything I could have imagined. Im very fortunate to not only be alive, but to have been selected to speak at 2025 TEDxBoulder!

4287

Devin Effinger, Ph.D @deffinger.bsky.social · 18/07/2025

The inaugural #GRCPsychedelics was a success! I am honored to have been one of a few chosen to receive a travel award and be able to share the stage with the leaders in the field. 🙏 to the organizers! @alexkwan.bsky.social @vyazovskiy.bsky.social @melissaherman.bsky.social @viditavaidya.bsky.social

3349

Devin Effinger, Ph.D @deffinger.bsky.social · 04/05/2025

It’s a common misconception that, for the person with a SUD, the substances are the problem. In my experience, the real problem was much deeper. Until I addressed the underlying causes/conditions, longterm sobriety was unattainable. Link in bio. #sober #sobriety #sobersky #recovery

0112

Devin Effinger, Ph.D @deffinger.bsky.social · 04/02/2025

Winter brain 2025 was a blast! Our panel on microdosing #psychedelics was the most attended session of the conference. We covered 4 distinct areas: anecdotal/lived experience, preclinical neuroscience, clinical, and cardiovascular risk. Most people stayed after for a great discussion. #WCBR2025

0212

Devin Effinger, Ph.D @deffinger.bsky.social · 27/01/2025

Are you @winter_brain ?? Come check out our panel this afternoon on microdosing #psychedelics. Including lived experience, preclinical effects, clinical effects, and my work utilizing rodent echocardiogram to assess potential cardiovascular risks. #WCBR2025 🍄 @sthom003.bsky.social

091

Devin Effinger, Ph.D @deffinger.bsky.social · 11/12/2024

On tonight: Given that classical #psychedelics are 5-HT2B agonists, there is concern of a potential cardiovascular risk with prolonged use. To resemble human context, we chronically administered 2 low doses of LSD and performed echocardiograms at baseline, 4-, and 8-weeks. #ACNP2024

4246